Drugs / GSK704838
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00539825 | Sep 2007 → Feb 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK704838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00539825 ↗ |
| Known as | GSK704838C | “GSK704838C is a potent, pan-active mAChR antagonist, which is being developed for once-daily treatment of chronic obstructive pulmonary disease (COPD).” NCT00539825 ↗ |
| Action | Inhibit | “GSK704838C is a potent, pan-active mAChR antagonist” NCT00539825 ↗ |
| Route | Inhaled | “Single Inhaled Doses of GSK704838 and Tiotropium Bromide” NCT00539825 ↗ |